Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

About this update from Vivos Therapeutics, Inc.

LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City. Representing the Company, Kirk Hunstman, CEO, will deliver a corporate presentation at 11:30 am ET and will participate in one-on-one meetings with pre-qualified investors throughout the day. The Small Cap Showcase & WTR Insights brings together executive management teams from approximately 20 micro and small-cap companies across a diverse range of industries. This event provides a unique forum to discover differentiated investment opportunities through company presentations, one-on-one meetings, industry insights, and networking. For more information about The Small Cap Showcase & WTR Insights, please visit www.smallcapshowcase.com. A live webcast of the Company's presentation will be available at: Vivos Conference Webcast A replay of the presentation will be available following the event and may also be accessed through the Company's website under the Investor Relations section. About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children. OSA affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious ...

View stock analysis, news, and events for Vivos Therapeutics, Inc.